Public articles linked to the same research event.
Trends in biotechnology This review focuses on liquid biopsy for glioblastoma, noting that tissue biopsy is invasive and fails to capture tumor heterogeneity or temporal dynamics, while liquid biopsy can provide noninvasive real-time monitoring via circulating biomarkers such as cell-free DNA, circulating tumor DNA, circulating tumor cells, and extracellular vesicles in plasma, cerebrospinal fluid, urine, and saliva; it advances beyond prior biomarker catalogs by delivering a quantitative technology scorecard comparing cfDNA-, CTC-, and EV-based platforms in terms of sensitivity, clinical actionability, cost, and scalability, and introduces a multimodal decision matrix and an AI-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics to enhance minimal residual disease detection a
This review focuses on liquid biopsy for glioblastoma, noting that tissue biopsy is invasive and fails to capture tumor heterogeneity or temporal dynamics, while liquid biopsy can provide noninvasive real-time monitoring via circulating biomarkers such as cell-free DNA, circulating tumor DNA, circulating tumor cells, and extracellular vesicles in plasma, cerebrospinal fluid, urine, and saliva; it advances beyond prior biomarker catalogs by delivering a quantitative technology scorecard comparing cfDNA-, CTC-, and EV-based platforms in terms of sensitivity, clinical actionability, cost, and scalability, and introduces a multimodal decision matrix and an AI-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics to enhance minimal residual disease detection a
This review focuses on liquid biopsy for glioblastoma, noting that tissue biopsy is invasive and fails to capture tumor heterogeneity or temporal dynamics, while liquid biopsy can provide noninvasive real-time monitoring via circulating biomarkers such as cell-free DNA, circulating tumor DNA, circulating tumor cells, and extracellular vesicles in plasma, cerebrospinal fluid, urine, and saliva; it advances beyond prior biomarker catalogs by delivering a quantitative technology scorecard comparing cfDNA-, CTC-, and EV-based platforms in terms of sensitivity, clinical actionability, cost, and scalability, and introduces a multimodal decision matrix and an AI-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics to enhance minimal residual disease detection a
This review focuses on liquid biopsy for glioblastoma, noting that tissue biopsy is invasive and fails to capture tumor heterogeneity or temporal dynamics, while liquid biopsy can provide noninvasive real-time monitoring via circulating biomarkers such as cell-free DNA, circulating tumor DNA, circulating tumor cells, and extracellular vesicles in plasma, cerebrospinal fluid, urine, and saliva; it advances beyond prior biomarker catalogs by delivering a quantitative technology scorecard comparing cfDNA-, CTC-, and EV-based platforms in terms of sensitivity, clinical actionability, cost, and scalability, and introduces a multimodal decision matrix and an AI-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics to enhance minimal residual disease detection a